Protocol Ledger

NCT07876557 · Phase II · RECRUITING

A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

Interventional Phase II clinical trial protocol NCT07876557 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-10-22 Enrollment: 184 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07876557
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)184 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07876557
Protocol FieldVerified Registry Value
NCT IdentifierNCT07876557
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment184 participants (ESTIMATED)
Registered Start Date2026-10-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI